Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Does NSAID protect against Post-ERCP Pancreatitis?
2017-004250-42Phase 4Terminated
- Sponsor
- Region Västmanland
- Start
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of diclofenac in post-endoscopic retrograde cholangiopancreatography pancreatitis (PEP) (2 arms), sponsored by Region Västmanland. Primary endpoint: Post-ERCP pancreatitis incidence. Started Jul 2018; status: terminated.
02
Drugs
diclofenac
03
Conditions
post-endoscopic retrograde cholangiopancreatography pancreatitis (PEP)
Beyond the preview
Go deeper on 2017-004250-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004250-42.